Tweet
Originally posted by AllSeq
View Post
-
Brilliant move or sign of desperation on the part of Roche? After sending $60M+ down the drain with IBM they are now back to the big dance, now with (apparently) murky IP situation. ONT has licensed so much IP on the biochemistry side that it is not clear (to me) how Genia works around that. Judging from the patents that are now published, the sensors themselves are interesting but not terribly unique. The guys know their analog design (duh), but without biochemistry they will go nowhere. Maybe this is what Roche is banking on - take the platform and add their own biochemistry. -
Genia seems to be claiming two advantages:Originally posted by BBoy View Post
1) Precise control over the nanopore assembly process, allowing for 'better than Poisson' distribution
2) NanoTag biochemistry (being co-developed with Columbia and Harvard)
Do you not think this biochemistry confers an advantage (or are you saying they don't really 'own' it due to the murky nanopore IP situation)?Comment
-
Their hardware, as much as can be judged from their patents and public presentations is elegant. Murky biochem IP is indeed the right way to characterize things. There are multiple startups, universities, and established companies working in this area, some with overlapping IP claims. It will be interesting to sit back and watch the lawyers get paid large amounts of money to argue about trivialities.Originally posted by AllSeq View PostComment
-
I'm curious about this part as well. I wonder if Thermo Fisher dumped any ties with Genia after the Life acquisition?Originally posted by scbaker View PostComment
-
Still haven't heard anything else about the group working on Starlight.Originally posted by snetmcom View Post
As for Thermo, my assumption is they still own a portion Genia and will make a bit of money on their investment once the acquisition closes.Comment
-
During the COVID-19 pandemic, scientists observed that while some individuals experienced severe illness when infected with SARS-CoV-2, others were barely affected. These disparities left researchers and clinicians wondering what causes the wide variations in response to viral infections and what role genetics plays.
Jean-Laurent Casanova, M.D., Ph.D., Professor at Rockefeller University, is a leading expert in this crossover between genetics and infectious...09-09-2024, 10:59 AM -
The first FDA-approved CRISPR-based therapy marked the transition of therapeutic gene editing from a dream to reality1. CRISPR technologies have streamlined gene editing, and CRISPR screens have become an important approach for identifying genes involved in disease processes2. This technique introduces targeted mutations across numerous genes, enabling large-scale identification of gene functions, interactions, and pathways3. Identifying the full range...08-27-2024, 04:44 AM
Comment